Prelude, Lilly to Evaluate PRT13722 in Breast Cancer Trial
Prelude announced a clinical trial collaboration and supply agreement with Lilly to evaluate its KAT6A selective degrader PRT13722 alongside Verzenio and Inluriyo in patients with HR+/HER2- breast cancer.
Story updates
11:07:03 AM UTC
SquawkNews
Combination cohorts are part of Prelude’s Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026The collaboration is underpinned by pre-clinical data that demonstrate monotherapy efficacy for PRT13722 and synergy wit…
11:07:22 AM UTC
SquawkNews
Prelude announced a clinical trial collaboration and supply agreement with Lilly to evaluate PRT13722 with abemaciclib and imlunestrant in HR+/HER2- breast cancer. FDA cleared the IND; Phase 1 enrollment is expected to begin in Q4 2026.Material DetailsContext by AI AnalystThis is an early-stage dev…